BioMarin Pharmaceuticals BMRN EPS (Basic)
EPS (Basic) at other companies
Other financials
Where this comes from
Reported directly by BioMarin Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareBasic.
The official record: BioMarin Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioMarin Pharmaceuticals's eps (basic).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is BioMarin Pharmaceuticals's EPS (basic)?
- BioMarin Pharmaceuticals (BMRN) reported EPS (basic) of $0.55 in Q1 2026.
- How has BioMarin Pharmaceuticals's EPS (basic) changed year-over-year?
- BioMarin Pharmaceuticals's EPS (basic) decreased by 43.3% year-over-year, from $0.97 to $0.55.
- What is the long-term trend for BioMarin Pharmaceuticals's EPS (basic)?
- Over 3 years (2021 to 2024), BioMarin Pharmaceuticals's EPS (basic) has grown at a 85.9% compound annual growth rate (CAGR), from -$0.35 to $2.25.
- What does EPS (basic) mean?
- The profit allocated to each share of common stock currently outstanding.
- How do you interpret EPS (basic)?
- An increase suggests higher profitability per share, which is generally positive for stock valuation.
- How does EPS (basic) compare across companies?
- Widely used by investors to compare valuation multiples like P/E ratios across the industry.